Lung disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:52 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lung disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Osimertinib for Patients with EGFR Mutant Non-Small Cell Lung Cancer Based on TP53 Mutation Status https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-osimertinib-for-patients-with-egfr-mutant-non-small-cell-lung-cancer-based-on-tp53-mutation-status/ Wed, 29 Apr 2026 15:02:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-osimertinib-for-patients-with-egfr-mutant-non-small-cell-lung-cancer-based-on-tp53-mutation-status/ This clinical trial is focused on studying a type of lung cancer known as EGFR mutant non-small cell lung cancer (NSCLC). This specific form of lung cancer involves changes in the EGFR gene, which can affect how cancer cells grow. The study is particularly interested in understanding how another gene, called TP53, influences the effectiveness of the treatment. The treatment being tested in this study is a medication called osimertinib, which is also known by its code name AZD9291. Osimertinib is taken as a film-coated tablet and is designed to target and block the activity of the EGFR gene mutations in cancer cells.

The purpose of this study is to evaluate how well osimertinib works in patients who have not received any previous treatment for their advanced EGFR mutant NSCLC. Participants in the study will take osimertinib orally, and the study will monitor their progress over time. The study aims to understand how the presence of the TP53 mutation affects the treatment’s success in controlling the cancer. The trial will follow patients to see how long they can live without the cancer getting worse, which is known as progression-free survival.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the cancer’s response to the treatment. These tests may include imaging techniques like computed tomography (CT) or magnetic resonance imaging (MRI) to measure the size of the cancer. The study will help gather important information on the effectiveness of osimertinib for patients with this specific type of lung cancer, potentially leading to better treatment options in the future.

]]> Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19 https://clinicaltrials.eu/trial/study-on-baricitinib-for-hospitalized-patients-with-severe-or-critical-covid-19/ Wed, 29 Apr 2026 14:25:18 +0000 https://clinicaltrials.eu/trial/study-on-baricitinib-for-hospitalized-patients-with-severe-or-critical-covid-19/ This clinical trial is focused on studying the effects of a medication called baricitinib on patients with COVID-19, which is caused by the SARS-CoV-2 virus. The study aims to understand how this medication, when added to the standard care, affects the progression of the disease in hospitalized patients who are immunocompromised, meaning their immune system is weakened. The trial will compare the effects of baricitinib to a placebo, which is a substance with no active medication, to see if there is a difference in outcomes.

The purpose of the study is to determine if baricitinib can help reduce the risk of death in patients with severe or critical COVID-19. Participants in the study will receive either the medication or a placebo, and their health will be monitored to see how the disease progresses. The study will look at whether the medication can prevent the disease from getting worse and if it can help patients recover more quickly.

Throughout the study, participants will be closely observed to track their recovery and any changes in their condition. The trial will also assess various health markers to understand the impact of the treatment. This research is part of a larger effort to find effective treatments for COVID-19 and improve outcomes for patients with this disease.

]]> Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bemcentinib-for-hospitalized-patients-with-moderate-covid-19/ Wed, 29 Apr 2026 14:25:16 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bemcentinib-for-hospitalized-patients-with-moderate-covid-19/ This clinical trial is focused on studying the treatment of COVID-19, a disease caused by the SARS-CoV-2 virus, which can lead to respiratory symptoms and other health issues. The treatment being tested is a medication called Bemcentinib, which is taken in capsule form. Bemcentinib is a type of drug known as a receptor tyrosine kinase inhibitor, which means it works by blocking certain proteins that may help the virus spread in the body. The study will compare the effects of Bemcentinib combined with standard care to a placebo combined with standard care in patients who are hospitalized with moderate COVID-19.

The purpose of the study is to evaluate how effective Bemcentinib is in improving the condition of patients with moderate COVID-19. Participants in the study will receive either Bemcentinib or a placebo, along with the usual care provided in hospitals. The study will monitor the patients’ health over a period of time to see if there are any changes in their condition, such as improvement or worsening of symptoms. The study will also look at other factors, such as how quickly patients recover and any side effects they may experience.

Throughout the study, various health indicators will be assessed, including the patients’ disease state on a scale used by the World Health Organization (WHO) and the levels of oxygen in their blood. The study will also track the occurrence of any serious health events and the time it takes for patients to be discharged from the hospital. By the end of the study, researchers hope to gather valuable information about the potential benefits and safety of using Bemcentinib to treat COVID-19.

]]>